id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-E-1059-0007,FDA,FDA-2019-E-1059,Letter from U. S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-01-17T05:00:00Z,2024,1,2024-01-17T05:00:00Z,,2024-01-17T19:08:51Z,,0,0,0900006486389648
FDA-2019-E-1059-0006,FDA,FDA-2019-E-1059,Patent Term Extension Letter from FDA CDER to U S Patent Trademark Office,Other,Letter(s),2020-07-27T04:00:00Z,2020,7,2020-07-28T04:00:00Z,,2020-07-28T13:44:35Z,,0,0,09000064847ad200
FDA-2019-E-1059-0005,FDA,FDA-2019-E-1059,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2020-06-22T04:00:00Z,2020,6,2020-06-22T04:00:00Z,,2020-06-22T18:04:46Z,,0,0,09000064846ff19c
FDA-2019-E-1059-0004,FDA,FDA-2019-E-1059,Determination of Regulatory Review Period for Purposes of Patent Extension; ANDEXXA,Notice,Determinations,2019-12-05T05:00:00Z,2019,12,2019-12-05T05:00:00Z,2020-06-03T03:59:59Z,2019-12-05T15:56:38Z,2019-26251,0,0,09000064841e7454
FDA-2019-E-1059-0003,FDA,FDA-2019-E-1059,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2019-11-01T04:00:00Z,2019,11,2019-11-01T04:00:00Z,,2019-11-01T20:36:11Z,,0,0,090000648411687e
FDA-2019-E-1059-0002,FDA,FDA-2019-E-1059,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-05-13T04:00:00Z,2019,5,2019-05-13T04:00:00Z,,2019-05-13T17:58:22Z,,0,0,0900006483c728f3
FDA-2019-E-1059-0001,FDA,FDA-2019-E-1059,"Patent Extension Application for ANDEXXA Patent No. 8,153,590",Other,Application,2019-03-06T05:00:00Z,2019,3,2019-03-06T05:00:00Z,,2019-03-06T15:26:44Z,,0,0,0900006483ac36aa